

January 3, 2024

To,  
Mr. Sumit Kanchan  
Online Surveillance  
BSE Limited,  
Mumbai

Dear Sir,

**Sub: Clarification on increase in Volume - Glenmark Life Sciences Limited**

This has reference to the clarification sought by your good office vide your email bearing No. L/SURV/ONL/PV/VK/ 2023-2024 / 517 dated January 3, 2024 regarding significant increase in the volume of Company's securities across stock exchanges.

We wish to inform you that the Company has been disclosing the material information in accordance with applicable law, including Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("**Listing Regulations**"), its policy on determination of materiality for disclosures and its policy on the code of practices and procedures for fair disclosure of unpublished price sensitive information. The Company is aware and shall comply with its obligations under the applicable regulations and policies.

We hereby clarify that there is no information currently with the Company that is reportable to the stock exchanges pursuant to the Listing Regulations and relevant policies. We understand that the increase in volume of the Company's securities in the recent past is due to market conditions and is market driven.

The Company will continue to comply with the Listing Regulations and applicable policies in relation to dissemination of information.

Request you to kindly take the same on record.

Yours sincerely,  
For and on behalf of **Glenmark Life Sciences Limited**

**Rudalf Corriea**  
**Company Secretary & Compliance Officer**

**Glenmark Life Sciences Limited**

Corporate Office: 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri (E), Mumbai 400 099, India.

Registered Office: Plot No. 170-172, Chandramouli Industrial Estate, Mohol Bazarpath, Solapur - 413 213, India.

T: 91 22 68297979 CIN: L74900PN2011PLC139963 E: complianceofficer@glenmarklifesciences.com W: www.glenmarklifesciences.com